Open AccessBiosynthetic enzymes of the SARS-CoV-2 as potential targets for the discovery of new antiviral drugs
Author(s) -
Juan A. Castillo-Garit,
Yudith Cañizares-Carmenate,
Facundo Pérez-Giménez
Publication year - 2021
Publication title -
nereis
Language(s) - English
Resource type - Journals
eISSN - 2531-2545
pISSN - 1888-8550
DOI - 10.46583/nereis_2021.13.844
Subject(s) - drug repositioning , drug discovery , repurposing , coronavirus , covid-19 , virology , drug development , drug , antiviral drug , milestone , viral replication , disease , biology , medicine , computational biology , infectious disease (medical specialty) , virus , bioinformatics , pharmacology , history , ecology , archaeology , pathology
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised a major global health concern. This urgent situation is pressing the world to respond with the development of novel vaccine or small molecule therapeutics for SARS-CoV-2. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the discovery of such therapeutics. Direct-acting agents, targeting specific viral enzymes that play an essential role in viral replication, represent a milestone in antiviral therapy. Several biosynthetic enzymes of the SARS-CoV-2 were analyzed as potential targets to develop new therapeutic drugs. This work provides a basis and directions for future drug development and reuse on the protein level of COVID-19.